BibSonomy publications for /user/kanefendt/FluorescenceFri Feb 05 11:28:39 CET 2010Lung Cancer2160-165EGFR FISH versus mutation: different tests, different end-points602008& Analysis Carcinoma Clinical DNA Drug Epidermal Factor Fluorescence Growth Humans Hybridization In Inhibitors Kinase Lung Mutation Mutational Neoplasm Neoplasms Non-Small-Cell Patient Population Protein Receptor Resistance Selection Situ Topic Trials Tyrosine analysis antagonists as drug genetics identify inhibitors protein response therapeutic therapy use Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) demonstrated to significantly improve survival of non-small cell lung cancer patients (NSCLC) previously exposed to chemotherapy. Although clinical features, particularly smoking history, help physicians for identifying the sensitive population, a proper patient selection should not preclude to drug target assessment. EGFR mutations or increased EGFR gene copy number assessed by fluorescence in situ hybridization (FISH) identify NSCLC with the highest chance to respond to the therapy. Although indirect comparisons suggest that mutation analysis is the best available technique for identification of responders, survival improvement is not confined to individuals with tumor shrinkage. For patients with metastatic NSCLC, where definitive cure in not achievable, response is probably not the best end-point, since survival improvement observed with TKI included also patients with stable or progressive disease. Data from lFri Feb 05 11:28:39 CET 2010Clin.Cancer Res.185869-5876Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study14200880 Adult Aged Antibodies Colorectal Disease-Free Dosage Female Fluorescence Gene Genes Genetic Humans Hybridization In Male Markers Middle Monoclonal Mutation Neoplasms Prognosis Research Situ Survival analysis and drug erbB-1 genetics over response therapeutic therapy use PURPOSE: To evaluate the usefulness and the pitfalls inherent to the assessment of the epidermal growth factor receptor (EGFR) gene copy number (GCN) by fluorescence in situ hybridization (FISH) for outcome prediction to cetuximab in metastatic colorectal cancer. The value of testing KRAS mutation status, in addition to EGFR GCN, was also explored. EXPERIMENTAL DESIGN: FISH analysis of 87 metastatic colorectal cancer patients treated with cetuximab was done, recording individual GCN per cell and using different samples per tumor. Performances of published cutoff points and different summaries of EGFR GCN distribution were assessed for response prediction. RESULTS: In our data set, two published cutoff points performed less well than in their training set, yielding positive predictive values and negative predictive values between 40.0% and 48.3% and between 81.0% and 86.5%, respectively. Among summaries of GCN distribution explored, mean and right-tailed distribution of GCN yielded the Fri Feb 05 11:28:39 CET 2010Genes Dev.7773-783The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature162002Animals Biological Cytoplasm Diseases Factors Fluorescence Homeodomain Humans Lymphatic Mice Microscopy Models Proteins Research Suppressor System Time Tumor diagnosis embryology genetics metabolism physiology protein